Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

PR Newswire February 17, 2022

Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis

PR Newswire February 4, 2022

Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN

PR Newswire January 14, 2022

Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences

PR Newswire November 10, 2021

Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results

PR Newswire November 3, 2021

Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021

PR Newswire October 27, 2021

Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day

PR Newswire October 14, 2021

Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

PR Newswire September 7, 2021

Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference

PR Newswire October 10, 2017

Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch

PR Newswire October 2, 2017

Vanda to Present Scientific Posters at World Sleep 2017

PR Newswire September 29, 2017

Technical Reports on Biotech Equities -- Vanda Pharma, ACADIA Pharma, Achillion Pharma, and Agios Pharma

PR Newswire September 20, 2017

Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis

PR Newswire September 13, 2017

Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences

PR Newswire September 11, 2017

Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference

PR Newswire September 6, 2017

Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results

PR Newswire August 2, 2017

Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call

Accesswire August 2, 2017

Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

PR Newswire July 21, 2017

Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017

PR Newswire July 17, 2017

Technical Insights on Biotech Stocks -- Curis, OvaScience, Regulus Therapeutics, and Vanda Pharma

PR Newswire July 12, 2017